You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameFesoterodine
Accession NumberDB06702
TypeSmall Molecule
GroupsApproved
DescriptionFesoterodine is an antimuscarinic prodrug for the treatment of overactive bladder syndrome.
Structure
Thumb
Synonyms
FESO
Fesoterodine
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
ToviazTablet, extended release4 mgOralPfizer Canada Inc2012-04-19Not applicableCanada
ToviazTablet, extended release4 mgOralPfizer Limited2007-04-20Not applicableEu
ToviazTablet, film coated, extended release4 mg/1OralPhysicians Total Care, Inc.2010-08-23Not applicableUs
ToviazTablet, extended release8 mgOralPfizer Limited2007-04-20Not applicableEu
ToviazTablet, film coated, extended release8 mg/1OralPfizer Laboratories Div Pfizer Inc2008-10-31Not applicableUs
ToviazTablet, extended release4 mgOralPfizer Limited2007-04-20Not applicableEu
ToviazTablet, extended release8 mgOralPfizer Limited2007-04-20Not applicableEu
ToviazTablet, film coated, extended release8 mg/1OralU.S. Pharmaceuticals2008-10-31Not applicableUs
ToviazTablet, extended release4 mgOralPfizer Limited2007-04-20Not applicableEu
ToviazTablet, extended release8 mgOralPfizer Canada Inc2012-04-19Not applicableCanada
ToviazTablet, extended release8 mgOralPfizer Limited2007-04-20Not applicableEu
ToviazTablet, film coated, extended release8 mg/1OralPhysicians Total Care, Inc.2010-09-15Not applicableUs
ToviazTablet, extended release8 mgOralPfizer Limited2007-04-20Not applicableEu
ToviazTablet, extended release4 mgOralPfizer Limited2007-04-20Not applicableEu
ToviazTablet, extended release4 mgOralPfizer Limited2007-04-20Not applicableEu
ToviazTablet, film coated, extended release4 mg/1OralU.S. Pharmaceuticals2008-10-31Not applicableUs
ToviazTablet, extended release8 mgOralPfizer Limited2007-04-20Not applicableEu
ToviazTablet, extended release4 mgOralPfizer Limited2007-04-20Not applicableEu
ToviazTablet, extended release8 mgOralPfizer Limited2007-04-20Not applicableEu
ToviazTablet, film coated, extended release4 mg/1OralCardinal Health2008-10-31Not applicableUs
ToviazTablet, extended release8 mgOralPfizer Limited2007-04-20Not applicableEu
ToviazTablet, extended release4 mgOralPfizer Limited2007-04-20Not applicableEu
ToviazTablet, extended release8 mgOralPfizer Limited2007-04-20Not applicableEu
ToviazTablet, film coated, extended release4 mg/1OralAvera Mc Kennan Hospital2015-04-01Not applicableUs
ToviazTablet, extended release4 mgOralPfizer Limited2007-04-20Not applicableEu
ToviazTablet, extended release4 mgOralPfizer Limited2007-04-20Not applicableEu
ToviazTablet, extended release4 mgOralPfizer Limited2007-04-20Not applicableEu
ToviazTablet, extended release8 mgOralPfizer Limited2007-04-20Not applicableEu
ToviazTablet, film coated, extended release8 mg/1OralCardinal Health2008-10-31Not applicableUs
ToviazTablet, extended release8 mgOralPfizer Limited2007-04-20Not applicableEu
ToviazTablet, film coated, extended release4 mg/1OralPfizer Laboratories Div Pfizer Inc2008-10-31Not applicableUs
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International BrandsNot Available
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Fesoterodine fumarate
286930-03-8
Thumb
  • InChI Key: MWHXMIASLKXGBU-RNCYCKTQSA-N
  • Monoisotopic Mass: 527.288302671
  • Average Mass: 527.649
DBSALT000085
Categories
UNII621G617227
CAS number286930-02-7
WeightAverage: 411.5769
Monoisotopic: 411.277344055
Chemical FormulaC26H37NO3
InChI KeyDCCSDBARQIPTGU-HSZRJFAPSA-N
InChI
InChI=1S/C26H37NO3/c1-18(2)26(29)30-25-13-12-21(17-28)16-24(25)23(22-10-8-7-9-11-22)14-15-27(19(3)4)20(5)6/h7-13,16,18-20,23,28H,14-15,17H2,1-6H3/t23-/m1/s1
IUPAC Name
2-[(1R)-3-[bis(propan-2-yl)amino]-1-phenylpropyl]-4-(hydroxymethyl)phenyl 2-methylpropanoate
SMILES
CC(C)N(CC[[email protected]](C1=CC=CC=C1)C1=C(OC(=O)C(C)C)C=CC(CO)=C1)C(C)C
Pharmacology
IndicationFor the treatment of overactive bladder (with symptoms of urinary frequency, urgency, or urge incontinence).
Structured Indications
PharmacodynamicsFesoterodine is a prodrug. In-vivo it is broken down into its active metabolite, 5-hydroxymethyl tolterodine (5-HMT), by plasma esterases. The 5-hydroxymethyl metabolite, which exhibits an antimuscarinic activity. Both urinary bladder contraction and salivation are mediated via cholinergic muscarinic receptors. Therefore, acting as a competitive muscarinic receptor antagonist, fesoterodine ultimately acts to decrease the detrusor pressure by its muscarinic antagonism, thereby decreasing bladder contraction and consequently, the urge to urinate.
Mechanism of actionFesoterodine, once converted to its active metabolite, 5-hydroxymethyltolterodine, acts as a competitive antagonists at muscarinic receptors. This results in the inhibition of bladder contraction, decrease in detrusor pressure, and an incomplete emptying of the bladder.
TargetKindPharmacological actionActionsOrganismUniProt ID
Muscarinic acetylcholine receptor M3Proteinyes
antagonist
HumanP20309 details
Muscarinic acetylcholine receptor M4Proteinunknown
antagonist
HumanP08173 details
Muscarinic acetylcholine receptor M1Proteinunknown
antagonist
HumanP11229 details
Muscarinic acetylcholine receptor M2Proteinunknown
antagonist
HumanP08172 details
Muscarinic acetylcholine receptor M5Proteinunknown
antagonist
HumanP08912 details
Related Articles
AbsorptionTmax (5-HMT): 5 hours post-adminitration of fesoterodine. AUC (0,∞)= 49.5 ng·h/ ml Bioavailability, 5-HMT = 52%
Volume of distribution

IV, 5-HMT: 169 L

Protein binding5-HMT: 50% to albumin and alpha1-acid glycoprotein
Metabolism

Metabolized by ubiquitous, nonspecific esterases to transform fesoterodine into 5-HMT Extensive metabolism via CYP2D6 and CYP3A4 into inactive metabolites

Route of eliminationRenal: 70% of fesoterodine was recovered in urine as 5-HMT; 35% carboxy metabolite; 18% carboxy-N-desisopropylmetabolite, and 1% N-desisopropyl metabolite Fecal: 7% Hepatic: fesoterodine elimination via CYP2D6 and CYP3A4
Half life7-8 hours for the active metabolite 5-hydroxymethyl tolterodine
Clearance

5-HMT, healthy subjects: 14.4 L/h
5-HMT is also secreted into the nephron.

ToxicityRat, Oral, LD50: ~ 681 mg/kg Mouse, Oral, LD50: ~ 316 mg/kg Rat, Intravenous, NOAEL: 10 mg/kg Mouse, Intravenous, NOAEL: 10 mg/kg
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
1,10-PhenanthrolineThe therapeutic efficacy of Fesoterodine can be decreased when used in combination with 1,10-Phenanthroline.Experimental
AbirateroneThe serum concentration of Fesoterodine can be increased when it is combined with Abiraterone.Approved
AcebutololThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Acebutolol.Approved
AcetaminophenThe serum concentration of Fesoterodine can be increased when it is combined with Acetaminophen.Approved
AclidiniumAclidinium may increase the anticholinergic activities of Fesoterodine.Approved
AfatinibThe serum concentration of Fesoterodine can be increased when it is combined with Afatinib.Approved
AjmalineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Ajmaline.Approved
AlbendazoleThe serum concentration of Fesoterodine can be increased when it is combined with Albendazole.Approved, Vet Approved
AldosteroneThe serum concentration of Fesoterodine can be decreased when it is combined with Aldosterone.Experimental
AlectinibThe serum concentration of Fesoterodine can be increased when it is combined with Alectinib.Approved
AlfentanilThe serum concentration of Fesoterodine can be increased when it is combined with Alfentanil.Approved, Illicit
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Fesoterodine is combined with Alphacetylmethadol.Experimental, Illicit
AmantadineThe serum concentration of Fesoterodine can be increased when it is combined with Amantadine.Approved
AmbenoniumThe therapeutic efficacy of Fesoterodine can be decreased when used in combination with Ambenonium.Approved
Aminohippuric acidThe serum concentration of Fesoterodine can be increased when it is combined with Aminohippuric acid.Approved
AmiodaroneThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Amiodarone.Approved, Investigational
AmitriptylineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Amitriptyline.Approved
AmlodipineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Amlodipine.Approved
AmodiaquineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Amodiaquine.Approved
AmphetamineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Amphetamine.Approved, Illicit
AmprenavirThe serum concentration of Fesoterodine can be decreased when it is combined with Amprenavir.Approved
AmsacrineThe serum concentration of Fesoterodine can be increased when it is combined with Amsacrine.Approved
Anisotropine MethylbromideThe risk or severity of adverse effects can be increased when Anisotropine Methylbromide is combined with Fesoterodine.Approved
AntipyrineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Antipyrine.Approved
AprepitantThe serum concentration of Fesoterodine can be increased when it is combined with Aprepitant.Approved, Investigational
AripiprazoleThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Aripiprazole.Approved, Investigational
ArtemetherThe metabolism of Fesoterodine can be decreased when combined with Artemether.Approved
AsenapineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Asenapine.Approved
AstemizoleThe serum concentration of Fesoterodine can be increased when it is combined with Astemizole.Approved, Withdrawn
AtazanavirThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Atazanavir.Approved, Investigational
AtenololThe serum concentration of Fesoterodine can be increased when it is combined with Atenolol.Approved
AtomoxetineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Atomoxetine.Approved
AtorvastatinThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Atorvastatin.Approved
Atracurium besylateThe risk or severity of adverse effects can be increased when Atracurium besylate is combined with Fesoterodine.Approved
AtropineThe risk or severity of adverse effects can be increased when Atropine is combined with Fesoterodine.Approved, Vet Approved
AzelastineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Azelastine.Approved
AzithromycinThe serum concentration of Fesoterodine can be increased when it is combined with Azithromycin.Approved
BenactyzineThe risk or severity of adverse effects can be increased when Fesoterodine is combined with Benactyzine.Withdrawn
BendroflumethiazideThe serum concentration of Bendroflumethiazide can be increased when it is combined with Fesoterodine.Approved
BenzatropineThe risk or severity of adverse effects can be increased when Benzatropine is combined with Fesoterodine.Approved
BenzocaineThe serum concentration of Fesoterodine can be increased when it is combined with Benzocaine.Approved
BepridilThe serum concentration of Fesoterodine can be increased when it is combined with Bepridil.Approved, Withdrawn
BetaxololThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Betaxolol.Approved
BexaroteneThe serum concentration of Fesoterodine can be decreased when it is combined with Bexarotene.Approved, Investigational
BezitramideThe risk or severity of adverse effects can be increased when Fesoterodine is combined with Bezitramide.Experimental, Illicit, Withdrawn
BicalutamideThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Bicalutamide.Approved
BiperidenThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Biperiden.Approved
BoceprevirThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Boceprevir.Approved
BortezomibThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Bortezomib.Approved, Investigational
BosentanThe serum concentration of Fesoterodine can be decreased when it is combined with Bosentan.Approved, Investigational
BosutinibThe serum concentration of Fesoterodine can be increased when it is combined with Bosutinib.Approved
Botulinum Toxin Type AFesoterodine may increase the anticholinergic activities of Botulinum Toxin Type A.Approved, Investigational
Botulinum Toxin Type BFesoterodine may increase the anticholinergic activities of Botulinum Toxin Type B.Approved
BromocriptineThe serum concentration of Fesoterodine can be increased when it is combined with Bromocriptine.Approved, Investigational
BrompheniramineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Brompheniramine.Approved
BuprenorphineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BupropionThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Bupropion.Approved
BuspironeThe serum concentration of Fesoterodine can be increased when it is combined with Buspirone.Approved, Investigational
ButorphanolThe risk or severity of adverse effects can be increased when Fesoterodine is combined with Butorphanol.Approved, Illicit, Vet Approved
CabazitaxelThe serum concentration of Fesoterodine can be increased when it is combined with Cabazitaxel.Approved
CaffeineThe serum concentration of Fesoterodine can be increased when it is combined with Caffeine.Approved
CanagliflozinThe serum concentration of Fesoterodine can be increased when it is combined with Canagliflozin.Approved
CandesartanThe serum concentration of Fesoterodine can be increased when it is combined with Candesartan.Approved
CaptoprilThe serum concentration of Fesoterodine can be increased when it is combined with Captopril.Approved
CarbamazepineThe metabolism of Fesoterodine can be increased when combined with Carbamazepine.Approved, Investigational
CarbinoxamineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Carbinoxamine.Approved
CarfentanilThe risk or severity of adverse effects can be increased when Fesoterodine is combined with Carfentanil.Illicit, Vet Approved
CarteololThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Carteolol.Approved
CarvedilolThe serum concentration of Fesoterodine can be increased when it is combined with Carvedilol.Approved, Investigational
CaspofunginThe serum concentration of Fesoterodine can be increased when it is combined with Caspofungin.Approved
CelecoxibThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Celecoxib.Approved, Investigational
CeritinibThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Ceritinib.Approved
CerivastatinThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Cerivastatin.Withdrawn
ChloroquineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Chloroquine.Approved, Vet Approved
ChlorothiazideThe serum concentration of Chlorothiazide can be increased when it is combined with Fesoterodine.Approved, Vet Approved
ChlorphenamineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Chlorphenamine.Approved
ChlorphenoxamineThe risk or severity of adverse effects can be increased when Fesoterodine is combined with Chlorphenoxamine.Withdrawn
ChlorpromazineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Chlorpromazine.Approved, Vet Approved
ChlorpropamideThe serum concentration of Fesoterodine can be increased when it is combined with Chlorpropamide.Approved
ChlorprothixeneThe serum concentration of Fesoterodine can be increased when it is combined with Chlorprothixene.Approved, Withdrawn
ChlorthalidoneThe serum concentration of Chlorthalidone can be increased when it is combined with Fesoterodine.Approved
CholecalciferolThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Cholecalciferol.Approved, Nutraceutical
CholesterolThe serum concentration of Fesoterodine can be increased when it is combined with Cholesterol.Experimental
Cholic AcidThe serum concentration of Fesoterodine can be decreased when it is combined with Cholic Acid.Approved
CilazaprilThe serum concentration of Fesoterodine can be increased when it is combined with Cilazapril.Approved
CimetidineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Cimetidine.Approved
CimetropiumFesoterodine may increase the anticholinergic activities of Cimetropium.Experimental
CinacalcetThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Cinacalcet.Approved
CiprofloxacinThe serum concentration of Fesoterodine can be increased when it is combined with Ciprofloxacin.Approved, Investigational
CisaprideThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Cisapride.Approved, Investigational, Withdrawn
CitalopramThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Citalopram.Approved
ClarithromycinThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Clarithromycin.Approved
ClemastineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Clemastine.Approved
ClobazamThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Clobazam.Approved, Illicit
ClofazimineThe serum concentration of Fesoterodine can be increased when it is combined with Clofazimine.Approved, Investigational
ClomipramineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Clomipramine.Approved, Vet Approved
ClotrimazoleThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Clotrimazole.Approved, Vet Approved
ClozapineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Clozapine.Approved
CobicistatThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Cobicistat.Approved
CocaineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Cocaine.Approved, Illicit
CodeineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Codeine.Approved, Illicit
ColchicineThe serum concentration of Fesoterodine can be increased when it is combined with Colchicine.Approved
ColforsinThe serum concentration of Fesoterodine can be increased when it is combined with Colforsin.Experimental
ConivaptanThe serum concentration of Fesoterodine can be increased when it is combined with Conivaptan.Approved, Investigational
CoumaphosThe therapeutic efficacy of Fesoterodine can be decreased when used in combination with Coumaphos.Vet Approved
CrizotinibThe metabolism of Fesoterodine can be decreased when combined with Crizotinib.Approved
CyclopentolateThe risk or severity of adverse effects can be increased when Cyclopentolate is combined with Fesoterodine.Approved
CyclophosphamideThe serum concentration of Fesoterodine can be increased when it is combined with Cyclophosphamide.Approved, Investigational
CyclosporineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Cyclosporine.Approved, Investigational, Vet Approved
DabrafenibThe serum concentration of Fesoterodine can be decreased when it is combined with Dabrafenib.Approved
DaclatasvirThe serum concentration of Fesoterodine can be increased when it is combined with Daclatasvir.Approved
DactinomycinThe serum concentration of Fesoterodine can be increased when it is combined with Dactinomycin.Approved
DarifenacinThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Darifenacin.Approved, Investigational
DarunavirThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Darunavir.Approved
DasatinibThe serum concentration of Fesoterodine can be increased when it is combined with Dasatinib.Approved, Investigational
DaunorubicinThe serum concentration of Fesoterodine can be decreased when it is combined with Daunorubicin.Approved
DecamethoniumThe therapeutic efficacy of Fesoterodine can be decreased when used in combination with Decamethonium.Approved
DeferasiroxThe serum concentration of Fesoterodine can be decreased when it is combined with Deferasirox.Approved, Investigational
DelavirdineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Delavirdine.Approved
DemecariumThe therapeutic efficacy of Fesoterodine can be decreased when used in combination with Demecarium.Approved
DesipramineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Desipramine.Approved
DesloratadineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Desloratadine.Approved, Investigational
DexamethasoneThe serum concentration of Fesoterodine can be decreased when it is combined with Dexamethasone.Approved, Investigational, Vet Approved
DexetimideThe risk or severity of adverse effects can be increased when Fesoterodine is combined with Dexetimide.Withdrawn
DexfenfluramineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Dexfenfluramine.Approved, Illicit, Withdrawn
DexmedetomidineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Dexmedetomidine.Approved, Vet Approved
DexmethylphenidateThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Dexmethylphenidate.Approved
DextroamphetamineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Dextroamphetamine.Approved, Illicit
DextromethorphanThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Dextromethorphan.Approved
DextromoramideThe risk or severity of adverse effects can be increased when Fesoterodine is combined with Dextromoramide.Experimental, Illicit
DextropropoxypheneThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Dextropropoxyphene.Approved, Illicit, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Fesoterodine is combined with Dezocine.Approved
DichlorvosThe therapeutic efficacy of Fesoterodine can be decreased when used in combination with Dichlorvos.Vet Approved
DiclofenacThe serum concentration of Fesoterodine can be increased when it is combined with Diclofenac.Approved, Vet Approved
DicyclomineThe risk or severity of adverse effects can be increased when Dicyclomine is combined with Fesoterodine.Approved
DigoxinThe serum concentration of Fesoterodine can be decreased when it is combined with Digoxin.Approved
DihydrocodeineThe risk or severity of adverse effects can be increased when Fesoterodine is combined with Dihydrocodeine.Approved, Illicit
DihydroergotamineThe metabolism of Fesoterodine can be decreased when combined with Dihydroergotamine.Approved
DihydroetorphineThe risk or severity of adverse effects can be increased when Fesoterodine is combined with Dihydroetorphine.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Fesoterodine is combined with Dihydromorphine.Experimental, Illicit
DiltiazemThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Diltiazem.Approved
Dimethyl sulfoxideThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Dimethyl sulfoxide.Approved, Vet Approved
DiphenhydramineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Diphenhydramine.Approved
DiphenoxylateThe risk or severity of adverse effects can be increased when Fesoterodine is combined with Diphenoxylate.Approved, Illicit
DipyridamoleThe serum concentration of Fesoterodine can be increased when it is combined with Dipyridamole.Approved
DonepezilThe therapeutic efficacy of Fesoterodine can be decreased when used in combination with Donepezil.Approved
DoxazosinThe serum concentration of Fesoterodine can be increased when it is combined with Doxazosin.Approved
DoxepinThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Doxepin.Approved
DoxorubicinThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Doxorubicin.Approved, Investigational
DoxycyclineThe metabolism of Fesoterodine can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DPDPEThe risk or severity of adverse effects can be increased when Fesoterodine is combined with DPDPE.Investigational
DronabinolFesoterodine may increase the tachycardic activities of Dronabinol.Approved, Illicit
DronedaroneThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Dronedarone.Approved
DuloxetineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Duloxetine.Approved
EchothiophateThe therapeutic efficacy of Fesoterodine can be decreased when used in combination with Echothiophate.Approved
EdrophoniumThe therapeutic efficacy of Fesoterodine can be decreased when used in combination with Edrophonium.Approved
EfavirenzThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Efavirenz.Approved, Investigational
ElbasvirThe serum concentration of Fesoterodine can be increased when it is combined with Elbasvir.Approved
EliglustatThe metabolism of Fesoterodine can be decreased when combined with Eliglustat.Approved
EluxadolineFesoterodine may increase the constipating activities of Eluxadoline.Approved
EnalaprilThe serum concentration of Fesoterodine can be increased when it is combined with Enalapril.Approved, Vet Approved
EnzalutamideThe serum concentration of Fesoterodine can be decreased when it is combined with Enzalutamide.Approved
EpinastineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Epinastine.Approved, Investigational
ErgonovineThe serum concentration of Fesoterodine can be increased when it is combined with Ergonovine.Approved
ErgotamineThe serum concentration of Fesoterodine can be increased when it is combined with Ergotamine.Approved
ErythromycinThe metabolism of Fesoterodine can be decreased when combined with Erythromycin.Approved, Vet Approved
EscitalopramThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Escitalopram.Approved, Investigational
Eslicarbazepine acetateThe serum concentration of Fesoterodine can be decreased when it is combined with Eslicarbazepine acetate.Approved
EstramustineThe serum concentration of Fesoterodine can be increased when it is combined with Estramustine.Approved
EstriolThe serum concentration of Fesoterodine can be decreased when it is combined with Estriol.Approved, Vet Approved
EstroneThe serum concentration of Fesoterodine can be decreased when it is combined with Estrone.Approved
EthanolEthanol may increase the central nervous system depressant (CNS depressant) activities of Fesoterodine.Approved
EthopropazineThe risk or severity of adverse effects can be increased when Ethopropazine is combined with Fesoterodine.Approved
EthylmorphineThe risk or severity of adverse effects can be increased when Fesoterodine is combined with Ethylmorphine.Approved, Illicit
EtoposideThe serum concentration of Fesoterodine can be increased when it is combined with Etoposide.Approved
EtoricoxibThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Etoricoxib.Approved, Investigational
EtorphineThe risk or severity of adverse effects can be increased when Fesoterodine is combined with Etorphine.Illicit, Vet Approved
EtravirineThe serum concentration of Fesoterodine can be decreased when it is combined with Etravirine.Approved
FelodipineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Felodipine.Approved, Investigational
FenfluramineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Fenfluramine.Illicit, Withdrawn
FentanylThe serum concentration of Fesoterodine can be increased when it is combined with Fentanyl.Approved, Illicit, Investigational, Vet Approved
FenthionThe therapeutic efficacy of Fesoterodine can be decreased when used in combination with Fenthion.Vet Approved
FexofenadineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Fexofenadine.Approved
FidaxomicinThe serum concentration of Fesoterodine can be increased when it is combined with Fidaxomicin.Approved
FlecainideThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Flecainide.Approved, Withdrawn
FluconazoleThe metabolism of Fesoterodine can be decreased when combined with Fluconazole.Approved
FluoxetineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Fluoxetine.Approved, Vet Approved
FlupentixolThe serum concentration of Fesoterodine can be increased when it is combined with Flupentixol.Approved, Withdrawn
FluphenazineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Fluphenazine.Approved
FlurazepamThe serum concentration of Fesoterodine can be increased when it is combined with Flurazepam.Approved, Illicit
FluvastatinThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Fluvastatin.Approved
FluvoxamineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Fluvoxamine.Approved, Investigational
FosamprenavirThe metabolism of Fesoterodine can be decreased when combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Fesoterodine can be increased when it is combined with Fosaprepitant.Approved
FosphenytoinThe metabolism of Fesoterodine can be increased when combined with Fosphenytoin.Approved
Fusidic AcidThe serum concentration of Fesoterodine can be increased when it is combined with Fusidic Acid.Approved
GalantamineThe therapeutic efficacy of Fesoterodine can be decreased when used in combination with Galantamine.Approved
Gallamine TriethiodideThe risk or severity of adverse effects can be increased when Gallamine Triethiodide is combined with Fesoterodine.Approved
GefitinibThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Gefitinib.Approved, Investigational
GenisteinThe serum concentration of Fesoterodine can be increased when it is combined with Genistein.Investigational
Ginkgo bilobaThe therapeutic efficacy of Fesoterodine can be decreased when used in combination with Ginkgo biloba.Approved, Nutraceutical
Glucagon recombinantThe risk or severity of adverse effects can be increased when Fesoterodine is combined with Glucagon recombinant.Approved
GlyburideThe serum concentration of Fesoterodine can be increased when it is combined with Glyburide.Approved
GlycerolThe serum concentration of Fesoterodine can be increased when it is combined with Glycerol.Experimental
GlycopyrroniumFesoterodine may increase the anticholinergic activities of Glycopyrronium.Approved, Investigational, Vet Approved
Gramicidin DThe serum concentration of Fesoterodine can be increased when it is combined with Gramicidin D.Approved
GranisetronThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Granisetron.Approved, Investigational
GrepafloxacinThe serum concentration of Fesoterodine can be increased when it is combined with Grepafloxacin.Withdrawn
HalofantrineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Halofantrine.Approved
HaloperidolThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Haloperidol.Approved
HeroinThe risk or severity of adverse effects can be increased when Fesoterodine is combined with Heroin.Approved, Illicit
HexamethoniumThe risk or severity of adverse effects can be increased when Fesoterodine is combined with Hexamethonium.Experimental
Histamine PhosphateThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Histamine Phosphate.Approved
HomatropineThe risk or severity of adverse effects can be increased when Fesoterodine is combined with Homatropine.Approved
Huperzine AThe therapeutic efficacy of Fesoterodine can be decreased when used in combination with Huperzine A.Investigational
HydrochlorothiazideThe serum concentration of Hydrochlorothiazide can be increased when it is combined with Fesoterodine.Approved, Vet Approved
HydrocodoneThe risk or severity of adverse effects can be increased when Fesoterodine is combined with Hydrocodone.Approved, Illicit
HydrocortisoneThe serum concentration of Fesoterodine can be increased when it is combined with Hydrocortisone.Approved, Vet Approved
HydroflumethiazideThe serum concentration of Hydroflumethiazide can be increased when it is combined with Fesoterodine.Approved
HydromorphoneThe risk or severity of adverse effects can be increased when Fesoterodine is combined with Hydromorphone.Approved, Illicit
HydroxychloroquineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Hydroxychloroquine.Approved
HydroxyureaThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Hydroxyurea.Approved
HydroxyzineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Hydroxyzine.Approved
HyoscyamineThe risk or severity of adverse effects can be increased when Hyoscyamine is combined with Fesoterodine.Approved
IdarubicinThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Idarubicin.Approved
IdelalisibThe serum concentration of Fesoterodine can be increased when it is combined with Idelalisib.Approved
ImatinibThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Imatinib.Approved
ImipramineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Imipramine.Approved
IndapamideThe serum concentration of Indapamide can be increased when it is combined with Fesoterodine.Approved
IndinavirThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Indinavir.Approved
indisulamThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with indisulam.Investigational
IndomethacinThe serum concentration of Fesoterodine can be increased when it is combined with Indomethacin.Approved, Investigational
Ipratropium bromideThe risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Fesoterodine.Approved
IrbesartanThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Irbesartan.Approved, Investigational
IsavuconazoniumThe metabolism of Fesoterodine can be decreased when combined with Isavuconazonium.Approved, Investigational
IsoflurophateThe therapeutic efficacy of Fesoterodine can be decreased when used in combination with Isoflurophate.Approved, Withdrawn
IsoniazidThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Isoniazid.Approved
IsradipineThe metabolism of Fesoterodine can be decreased when combined with Isradipine.Approved
ItoprideThe therapeutic efficacy of Itopride can be decreased when used in combination with Fesoterodine.Investigational
ItraconazoleThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Itraconazole.Approved, Investigational
IvacaftorThe serum concentration of Fesoterodine can be increased when it is combined with Ivacaftor.Approved
IvermectinThe serum concentration of Fesoterodine can be increased when it is combined with Ivermectin.Approved, Vet Approved
KetamineThe serum concentration of Fesoterodine can be increased when it is combined with Ketamine.Approved, Vet Approved
KetobemidoneThe risk or severity of adverse effects can be increased when Fesoterodine is combined with Ketobemidone.Approved
KetoconazoleThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Ketoconazole.Approved, Investigational
LabetalolThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Labetalol.Approved
LansoprazoleThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Lansoprazole.Approved, Investigational
LapatinibThe serum concentration of Fesoterodine can be increased when it is combined with Lapatinib.Approved, Investigational
LercanidipineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Lercanidipine.Approved, Investigational
LevofloxacinThe serum concentration of Fesoterodine can be increased when it is combined with Levofloxacin.Approved, Investigational
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Fesoterodine is combined with Levomethadyl Acetate.Approved
LevorphanolThe risk or severity of adverse effects can be increased when Fesoterodine is combined with Levorphanol.Approved
LevothyroxineThe serum concentration of Fesoterodine can be decreased when it is combined with Levothyroxine.Approved
LidocaineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Lidocaine.Approved, Vet Approved
LiothyronineThe serum concentration of Fesoterodine can be decreased when it is combined with Liothyronine.Approved, Vet Approved
LiotrixThe serum concentration of Fesoterodine can be decreased when it is combined with Liotrix.Approved
LisinoprilThe serum concentration of Fesoterodine can be increased when it is combined with Lisinopril.Approved, Investigational
LofentanilThe risk or severity of adverse effects can be increased when Fesoterodine is combined with Lofentanil.Illicit
LomitapideThe serum concentration of Fesoterodine can be increased when it is combined with Lomitapide.Approved
LomustineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Lomustine.Approved
LoperamideThe serum concentration of Fesoterodine can be increased when it is combined with Loperamide.Approved
LopinavirThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Lopinavir.Approved
LoratadineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Loratadine.Approved
LorcaserinThe metabolism of Fesoterodine can be decreased when combined with Lorcaserin.Approved
LosartanThe serum concentration of Fesoterodine can be increased when it is combined with Losartan.Approved
LovastatinThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Lovastatin.Approved, Investigational
LuliconazoleThe serum concentration of Fesoterodine can be increased when it is combined with Luliconazole.Approved
LumacaftorThe serum concentration of Fesoterodine can be decreased when it is combined with Lumacaftor.Approved
LumefantrineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Lumefantrine.Approved
MalathionThe therapeutic efficacy of Fesoterodine can be decreased when used in combination with Malathion.Approved, Investigational
MaprotilineThe serum concentration of Fesoterodine can be increased when it is combined with Maprotiline.Approved
MebendazoleThe serum concentration of Fesoterodine can be increased when it is combined with Mebendazole.Approved, Vet Approved
MecamylamineThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Fesoterodine.Approved
MefloquineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Mefloquine.Approved
Megestrol acetateThe serum concentration of Fesoterodine can be increased when it is combined with Megestrol acetate.Approved, Vet Approved
MemantineThe therapeutic efficacy of Fesoterodine can be decreased when used in combination with Memantine.Approved, Investigational
MeprobamateThe serum concentration of Fesoterodine can be increased when it is combined with Meprobamate.Approved, Illicit
MepyramineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Mepyramine.Approved, Vet Approved
MethadoneThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Methadone.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Fesoterodine is combined with Methadyl Acetate.Approved, Illicit
MethamphetamineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Methamphetamine.Approved, Illicit
Methanesulfonyl FluorideThe therapeutic efficacy of Fesoterodine can be decreased when used in combination with Methanesulfonyl Fluoride.Investigational
MethanthelineThe risk or severity of adverse effects can be increased when Methantheline is combined with Fesoterodine.Approved
MethazolamideThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Methazolamide.Approved
MethimazoleThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Methimazole.Approved
MethotrimeprazineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Methotrimeprazine.Approved
MethyclothiazideThe serum concentration of Methyclothiazide can be increased when it is combined with Fesoterodine.Approved
MethylnaltrexoneThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Methylnaltrexone.Approved
MethylphenidateThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Methylphenidate.Approved, Investigational
MetixeneThe risk or severity of adverse effects can be increased when Fesoterodine is combined with Metixene.Approved
MetoclopramideThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Metoclopramide.Approved, Investigational
MetolazoneThe serum concentration of Metolazone can be increased when it is combined with Fesoterodine.Approved
MetoprololThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Metoprolol.Approved, Investigational
MianserinThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Mianserin.Approved
MibefradilThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Mibefradil.Withdrawn
MiconazoleThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Miconazole.Approved, Investigational, Vet Approved
MidazolamThe serum concentration of Fesoterodine can be decreased when it is combined with Midazolam.Approved, Illicit
MidodrineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Midodrine.Approved
MifepristoneThe serum concentration of Fesoterodine can be increased when it is combined with Mifepristone.Approved, Investigational
MinaprineThe therapeutic efficacy of Fesoterodine can be decreased when used in combination with Minaprine.Approved
MirabegronThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Mirabegron.Approved
MirtazapineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Mirtazapine.Approved
MitomycinThe serum concentration of Fesoterodine can be increased when it is combined with Mitomycin.Approved
MitotaneThe serum concentration of Fesoterodine can be decreased when it is combined with Mitotane.Approved
MitoxantroneThe serum concentration of Fesoterodine can be decreased when it is combined with Mitoxantrone.Approved, Investigational
MoclobemideThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Moclobemide.Approved
ModafinilThe serum concentration of Fesoterodine can be decreased when it is combined with Modafinil.Approved, Investigational
MorphineThe serum concentration of Fesoterodine can be increased when it is combined with Morphine.Approved, Investigational
N-butylscopolammonium bromideThe risk or severity of adverse effects can be increased when Fesoterodine is combined with N-butylscopolammonium bromide.Vet Approved
NabiloneFesoterodine may increase the tachycardic activities of Nabilone.Approved, Investigational
NafcillinThe serum concentration of Fesoterodine can be decreased when it is combined with Nafcillin.Approved
NalbuphineThe risk or severity of adverse effects can be increased when Fesoterodine is combined with Nalbuphine.Approved
NaloxegolThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Naloxegol.Approved
NaltrexoneThe serum concentration of Fesoterodine can be increased when it is combined with Naltrexone.Approved, Investigational, Vet Approved
NaringeninThe serum concentration of Fesoterodine can be increased when it is combined with Naringenin.Experimental
NefazodoneThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Nefazodone.Approved, Withdrawn
NelfinavirThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Nelfinavir.Approved
NeostigmineThe therapeutic efficacy of Fesoterodine can be decreased when used in combination with Neostigmine.Approved, Vet Approved
NetupitantThe serum concentration of Fesoterodine can be increased when it is combined with Netupitant.Approved
NevirapineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Nevirapine.Approved
NiacinThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Niacin.Approved, Investigational, Nutraceutical
NicardipineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Nicardipine.Approved
NicotinamideThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Nicotinamide.Approved
NifedipineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Nifedipine.Approved
NilotinibThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Nilotinib.Approved, Investigational
NisoldipineThe serum concentration of Fesoterodine can be increased when it is combined with Nisoldipine.Approved
NitrazepamThe serum concentration of Fesoterodine can be increased when it is combined with Nitrazepam.Approved
NitrendipineThe serum concentration of Fesoterodine can be increased when it is combined with Nitrendipine.Approved
NorethisteroneThe serum concentration of Fesoterodine can be decreased when it is combined with Norethisterone.Approved
NormethadoneThe risk or severity of adverse effects can be increased when Fesoterodine is combined with Normethadone.Approved, Illicit
NortriptylineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Nortriptyline.Approved
NVA237The risk or severity of adverse effects can be increased when NVA237 is combined with Fesoterodine.Investigational
OlanzapineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Olanzapine.Approved, Investigational
OlaparibThe metabolism of Fesoterodine can be decreased when combined with Olaparib.Approved
OmeprazoleThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Omeprazole.Approved, Investigational, Vet Approved
OndansetronThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Ondansetron.Approved
OpiumThe risk or severity of adverse effects can be increased when Fesoterodine is combined with Opium.Approved, Illicit
OrphenadrineThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Fesoterodine.Approved
OsimertinibThe serum concentration of Fesoterodine can be increased when it is combined with Osimertinib.Approved
OxamniquineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Oxamniquine.Approved
OxprenololThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Oxprenolol.Approved
OxybutyninThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Oxybutynin.Approved, Investigational
OxycodoneThe risk or severity of adverse effects can be increased when Fesoterodine is combined with Oxycodone.Approved, Illicit, Investigational
OxymetholoneThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Oxymetholone.Approved, Illicit
OxymorphoneThe risk or severity of adverse effects can be increased when Fesoterodine is combined with Oxymorphone.Approved, Investigational, Vet Approved
OxyphenoniumThe risk or severity of adverse effects can be increased when Oxyphenonium is combined with Fesoterodine.Approved
P-NitrophenolThe serum concentration of Fesoterodine can be increased when it is combined with P-Nitrophenol.Experimental
PaclitaxelThe serum concentration of Fesoterodine can be increased when it is combined with Paclitaxel.Approved, Vet Approved
PalbociclibThe serum concentration of Fesoterodine can be increased when it is combined with Palbociclib.Approved
Palmitic AcidThe serum concentration of Fesoterodine can be increased when it is combined with Palmitic Acid.Experimental
PancuroniumThe risk or severity of adverse effects can be increased when Pancuronium is combined with Fesoterodine.Approved
PanobinostatThe serum concentration of Fesoterodine can be increased when it is combined with Panobinostat.Approved, Investigational
PantoprazoleThe serum concentration of Fesoterodine can be increased when it is combined with Pantoprazole.Approved
ParoxetineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Paroxetine.Approved, Investigational
Peginterferon alfa-2bThe serum concentration of Fesoterodine can be decreased when it is combined with Peginterferon alfa-2b.Approved
PentazocineThe risk or severity of adverse effects can be increased when Fesoterodine is combined with Pentazocine.Approved, Vet Approved
PentobarbitalThe metabolism of Fesoterodine can be increased when combined with Pentobarbital.Approved, Vet Approved
PentoliniumThe risk or severity of adverse effects can be increased when Pentolinium is combined with Fesoterodine.Approved
PergolideThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Pergolide.Approved, Vet Approved, Withdrawn
PerhexilineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Perhexiline.Approved
PerindoprilThe serum concentration of Fesoterodine can be increased when it is combined with Perindopril.Approved
PerphenazineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Perphenazine.Approved
PethidineThe risk or severity of adverse effects can be increased when Fesoterodine is combined with Pethidine.Approved
PhenobarbitalThe metabolism of Fesoterodine can be increased when combined with Phenobarbital.Approved
PhentermineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Phentermine.Approved, Illicit
PhenytoinThe metabolism of Fesoterodine can be increased when combined with Phenytoin.Approved, Vet Approved
PhysostigmineThe therapeutic efficacy of Fesoterodine can be decreased when used in combination with Physostigmine.Approved
PimozideThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Pimozide.Approved
PindololThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Pindolol.Approved
PioglitazoneThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Pioglitazone.Approved, Investigational
PipecuroniumThe risk or severity of adverse effects can be increased when Pipecuronium is combined with Fesoterodine.Approved
PipotiazineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Pipotiazine.Approved
PirenzepineThe risk or severity of adverse effects can be increased when Pirenzepine is combined with Fesoterodine.Approved
PiritramideThe risk or severity of adverse effects can be increased when Fesoterodine is combined with Piritramide.Investigational
Platelet Activating FactorThe serum concentration of Fesoterodine can be decreased when it is combined with Platelet Activating Factor.Experimental
PolythiazideThe serum concentration of Polythiazide can be increased when it is combined with Fesoterodine.Approved
PonatinibThe serum concentration of Fesoterodine can be increased when it is combined with Ponatinib.Approved
PosaconazoleThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Posaconazole.Approved, Investigational, Vet Approved
Potassium ChlorideFesoterodine may increase the ulcerogenic activities of Potassium Chloride.Approved, Withdrawn
PramlintidePramlintide may increase the anticholinergic activities of Fesoterodine.Approved, Investigational
PravastatinThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Pravastatin.Approved
PraziquantelThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Praziquantel.Approved, Vet Approved
PrazosinThe serum concentration of Fesoterodine can be increased when it is combined with Prazosin.Approved
PrednisoneThe serum concentration of Fesoterodine can be increased when it is combined with Prednisone.Approved, Vet Approved
PrimaquineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Primaquine.Approved
PrimidoneThe metabolism of Fesoterodine can be increased when combined with Primidone.Approved, Vet Approved
ProbenecidThe serum concentration of Fesoterodine can be increased when it is combined with Probenecid.Approved
ProcyclidineThe risk or severity of adverse effects can be increased when Procyclidine is combined with Fesoterodine.Approved
ProgesteroneThe serum concentration of Fesoterodine can be decreased when it is combined with Progesterone.Approved, Vet Approved
ProguanilThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Proguanil.Approved
PromazineThe metabolism of Fesoterodine can be decreased when combined with Promazine.Approved, Vet Approved
PromethazineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Promethazine.Approved
PropafenoneThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Propafenone.Approved
PropanthelineThe risk or severity of adverse effects can be increased when Propantheline is combined with Fesoterodine.Approved
PropiverineThe risk or severity of adverse effects can be increased when Fesoterodine is combined with Propiverine.Investigational
PropofolThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Propofol.Approved, Investigational, Vet Approved
PropranololThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Propranolol.Approved, Investigational
ProtriptylineThe serum concentration of Fesoterodine can be increased when it is combined with Protriptyline.Approved
PyridostigmineThe therapeutic efficacy of Fesoterodine can be decreased when used in combination with Pyridostigmine.Approved
PyrimethamineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Pyrimethamine.Approved, Vet Approved
QuercetinThe serum concentration of Fesoterodine can be increased when it is combined with Quercetin.Experimental
QuetiapineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Quetiapine.Approved
QuinacrineThe serum concentration of Fesoterodine can be increased when it is combined with Quinacrine.Approved
QuinethazoneThe serum concentration of Quinethazone can be increased when it is combined with Fesoterodine.Approved
QuinidineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Quinidine.Approved
QuinineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Quinine.Approved
RabeprazoleThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Rabeprazole.Approved, Investigational
RamosetronFesoterodine may increase the constipating activities of Ramosetron.Approved
RanitidineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Ranitidine.Approved
RanolazineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Ranolazine.Approved, Investigational
ReboxetineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Reboxetine.Approved, Investigational
RegorafenibThe serum concentration of Fesoterodine can be increased when it is combined with Regorafenib.Approved
RemifentanilThe risk or severity of adverse effects can be increased when Fesoterodine is combined with Remifentanil.Approved
ReserpineThe serum concentration of Fesoterodine can be decreased when it is combined with Reserpine.Approved
RifabutinThe metabolism of Fesoterodine can be increased when combined with Rifabutin.Approved
RifampicinThe metabolism of Fesoterodine can be increased when combined with Rifampicin.Approved
RifapentineThe metabolism of Fesoterodine can be increased when combined with Rifapentine.Approved
RilpivirineThe serum concentration of Fesoterodine can be increased when it is combined with Rilpivirine.Approved
RisperidoneThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Risperidone.Approved, Investigational
RitonavirThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Ritonavir.Approved, Investigational
RivastigmineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Rivastigmine.Approved, Investigational
RolapitantThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Rolapitant.Approved
RopiniroleThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Ropinirole.Approved, Investigational
RosiglitazoneThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Rosiglitazone.Approved, Investigational
RotigotineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Rotigotine.Approved
RutinThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Rutin.Experimental
SaquinavirThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Saquinavir.Approved, Investigational
ScopolamineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Fesoterodine.Approved
Scopolamine butylbromideThe risk or severity of adverse effects can be increased when Fesoterodine is combined with Scopolamine butylbromide.Approved
SecretinThe therapeutic efficacy of Secretin can be decreased when used in combination with Fesoterodine.Approved, Investigational
SelegilineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Selegiline.Approved, Investigational, Vet Approved
SertralineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Sertraline.Approved
SildenafilThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Sildenafil.Approved, Investigational
SiltuximabThe serum concentration of Fesoterodine can be decreased when it is combined with Siltuximab.Approved
SimeprevirThe serum concentration of Fesoterodine can be increased when it is combined with Simeprevir.Approved
SimvastatinThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Simvastatin.Approved
SirolimusThe serum concentration of Fesoterodine can be decreased when it is combined with Sirolimus.Approved, Investigational
SolifenacinThe risk or severity of adverse effects can be increased when Solifenacin is combined with Fesoterodine.Approved
SorafenibThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Sorafenib.Approved, Investigational
SparteineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Sparteine.Experimental
SpironolactoneThe serum concentration of Fesoterodine can be increased when it is combined with Spironolactone.Approved
St. John's WortThe serum concentration of Fesoterodine can be decreased when it is combined with St. John's Wort.Nutraceutical
StaurosporineThe serum concentration of Fesoterodine can be increased when it is combined with Staurosporine.Experimental
StiripentolThe serum concentration of Fesoterodine can be increased when it is combined with Stiripentol.Approved
StreptozocinThe serum concentration of Fesoterodine can be decreased when it is combined with Streptozocin.Approved
SufentanilThe risk or severity of adverse effects can be increased when Fesoterodine is combined with Sufentanil.Approved, Investigational
SulfanilamideThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Sulfanilamide.Approved
SulfaphenazoleThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Sulfaphenazole.Approved
SulfinpyrazoneThe serum concentration of Fesoterodine can be increased when it is combined with Sulfinpyrazone.Approved
SulfisoxazoleThe metabolism of Fesoterodine can be decreased when combined with Sulfisoxazole.Approved, Vet Approved
SulpirideThe therapeutic efficacy of Sulpiride can be decreased when used in combination with Fesoterodine.Approved
SumatriptanThe serum concentration of Fesoterodine can be increased when it is combined with Sumatriptan.Approved, Investigational
SunitinibThe serum concentration of Fesoterodine can be increased when it is combined with Sunitinib.Approved, Investigational
TacrineThe therapeutic efficacy of Fesoterodine can be decreased when used in combination with Tacrine.Withdrawn
TacrolimusThe serum concentration of Fesoterodine can be decreased when it is combined with Tacrolimus.Approved, Investigational
TamoxifenThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Tamoxifen.Approved
TapentadolThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Tapentadol.Approved
Taurocholic AcidThe serum concentration of Fesoterodine can be increased when it is combined with Taurocholic Acid.Experimental
TegaserodThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Tegaserod.Investigational, Withdrawn
TelaprevirThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Telaprevir.Approved
TelithromycinThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Telithromycin.Approved
TelmisartanThe serum concentration of Fesoterodine can be increased when it is combined with Telmisartan.Approved, Investigational
TemsirolimusThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Temsirolimus.Approved
TerazosinThe serum concentration of Fesoterodine can be increased when it is combined with Terazosin.Approved
TerbinafineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Terbinafine.Approved, Investigational, Vet Approved
TerfenadineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Terfenadine.Withdrawn
TesmilifeneThe serum concentration of Fesoterodine can be decreased when it is combined with Tesmilifene.Investigational
TestosteroneThe serum concentration of Fesoterodine can be increased when it is combined with Testosterone.Approved, Investigational
ThioridazineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Thioridazine.Approved
ThiothixeneThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Thiothixene.Approved
TicagrelorThe serum concentration of Fesoterodine can be increased when it is combined with Ticagrelor.Approved
TiclopidineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Ticlopidine.Approved
TiotropiumFesoterodine may increase the anticholinergic activities of Tiotropium.Approved
TipranavirThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Tipranavir.Approved, Investigational
TocilizumabThe serum concentration of Fesoterodine can be decreased when it is combined with Tocilizumab.Approved
TolterodineThe risk or severity of adverse effects can be increased when Tolterodine is combined with Fesoterodine.Approved, Investigational
TolvaptanThe serum concentration of Fesoterodine can be increased when it is combined with Tolvaptan.Approved
TopiramateThe risk or severity of adverse effects can be increased when Fesoterodine is combined with Topiramate.Approved
TramadolThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Tramadol.Approved, Investigational
TranylcypromineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Tranylcypromine.Approved
TrazodoneThe serum concentration of Fesoterodine can be decreased when it is combined with Trazodone.Approved, Investigational
TrichlorfonThe therapeutic efficacy of Fesoterodine can be decreased when used in combination with Trichlorfon.Vet Approved
TrichlormethiazideThe serum concentration of Trichlormethiazide can be increased when it is combined with Fesoterodine.Approved, Vet Approved
TrifluoperazineThe serum concentration of Fesoterodine can be increased when it is combined with Trifluoperazine.Approved
TriflupromazineThe serum concentration of Fesoterodine can be increased when it is combined with Triflupromazine.Approved, Vet Approved
TrihexyphenidylThe risk or severity of adverse effects can be increased when Trihexyphenidyl is combined with Fesoterodine.Approved
TrimethaphanThe risk or severity of adverse effects can be increased when Trimethaphan is combined with Fesoterodine.Approved
TrimethoprimThe serum concentration of Fesoterodine can be decreased when it is combined with Trimethoprim.Approved, Vet Approved
TrimipramineThe serum concentration of Fesoterodine can be increased when it is combined with Trimipramine.Approved
TripelennamineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Tripelennamine.Approved, Vet Approved
TriprolidineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Triprolidine.Approved
TroleandomycinThe serum concentration of Fesoterodine can be increased when it is combined with Troleandomycin.Approved
TropicamideThe risk or severity of adverse effects can be increased when Tropicamide is combined with Fesoterodine.Approved
TrospiumThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Trospium.Approved
TubocurarineThe risk or severity of adverse effects can be increased when Tubocurarine is combined with Fesoterodine.Approved
UmeclidiniumUmeclidinium may increase the anticholinergic activities of Fesoterodine.Approved
VecuroniumThe risk or severity of adverse effects can be increased when Vecuronium is combined with Fesoterodine.Approved
VemurafenibThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Vemurafenib.Approved
VenlafaxineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Venlafaxine.Approved
VerapamilThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Verapamil.Approved
VinblastineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Vinblastine.Approved
VincristineThe serum concentration of Fesoterodine can be decreased when it is combined with Vincristine.Approved, Investigational
VinorelbineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Vinorelbine.Approved, Investigational
VoriconazoleThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Voriconazole.Approved, Investigational
YohimbineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Yohimbine.Approved, Vet Approved
ZafirlukastThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Zafirlukast.Approved, Investigational
ZimelidineThe serum concentration of Fesoterodine can be increased when it is combined with Zimelidine.Withdrawn
ZiprasidoneThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Ziprasidone.Approved
Food Interactions
  • Take with or without food.
References
Synthesis Reference

Claus Meese, “CHIRAL INTERMEDIATE, PROCESS FOR PRODUCING THE SAME AND ITS USE IN THE MANUFACTURE OF TOLTERODINE, FESOTERODINE, OR THE ACTIVE METABOLITE THEREOF.” U.S. Patent US20090192224, issued July 30, 2009.

US20090192224
General References
  1. Malhotra B, Dickins M, Alvey C, Jumadilova Z, Li X, Duczynski G, Gandelman K: Effects of the moderate CYP3A4 inhibitor, fluconazole, on the pharmacokinetics of fesoterodine in healthy subjects. Br J Clin Pharmacol. 2011 Aug;72(2):263-9. doi: 10.1111/j.1365-2125.2011.04007.x. [PubMed:21545485 ]
  2. Malhotra B, Gandelman K, Sachse R, Wood N, Michel MC: The design and development of fesoterodine as a prodrug of 5-hydroxymethyl tolterodine (5-HMT), the active metabolite of tolterodine. Curr Med Chem. 2009;16(33):4481-9. [PubMed:19835561 ]
External Links
ATC CodesG04BD11
AHFS Codes
  • 12:08.08
PDB EntriesNot Available
FDA labelDownload (430 KB)
MSDSDownload (102 KB)
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9535
Blood Brain Barrier+0.5648
Caco-2 permeable+0.7699
P-glycoprotein substrateSubstrate0.5268
P-glycoprotein inhibitor INon-inhibitor0.5556
P-glycoprotein inhibitor IINon-inhibitor0.625
Renal organic cation transporterInhibitor0.6025
CYP450 2C9 substrateNon-substrate0.6853
CYP450 2D6 substrateNon-substrate0.5151
CYP450 3A4 substrateSubstrate0.5939
CYP450 1A2 substrateInhibitor0.6306
CYP450 2C9 inhibitorNon-inhibitor0.7227
CYP450 2D6 inhibitorInhibitor0.6255
CYP450 2C19 inhibitorNon-inhibitor0.7334
CYP450 3A4 inhibitorNon-inhibitor0.5718
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.6144
Ames testNon AMES toxic0.646
CarcinogenicityNon-carcinogens0.7213
BiodegradationNot ready biodegradable0.9385
Rat acute toxicity2.4003 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9196
hERG inhibition (predictor II)Inhibitor0.5602
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
PackagersNot Available
Dosage forms
FormRouteStrength
Tablet, extended releaseOral4 mg
Tablet, extended releaseOral8 mg
Tablet, film coated, extended releaseOral4 mg/1
Tablet, film coated, extended releaseOral8 mg/1
PricesNot Available
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US6858650 No2002-07-032022-07-03Us
US7384980 No1999-05-112019-05-11Us
US7807715 No2007-06-072027-06-07Us
US7855230 No1999-05-112019-05-11Us
US7985772 No1999-05-112019-05-11Us
US8088398 No2007-06-072027-06-07Us
US8338478 No1999-05-112019-05-11Us
US8501723 No2007-06-072027-06-07Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
water solubilityHighly soluble MSDS
Predicted Properties
PropertyValueSource
Water Solubility0.00205 mg/mLALOGPS
logP5.45ALOGPS
logP5.7ChemAxon
logS-5.3ALOGPS
pKa (Strongest Acidic)14.98ChemAxon
pKa (Strongest Basic)10.64ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area49.77 Å2ChemAxon
Rotatable Bond Count11ChemAxon
Refractivity124.08 m3·mol-1ChemAxon
Polarizability48.29 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability0ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as diphenylmethanes. These are compounds containing a diphenylmethane moiety, which consists of a methane wherein two hydrogen atoms are replaced by two phenyl groups.
KingdomOrganic compounds
Super ClassBenzenoids
ClassBenzene and substituted derivatives
Sub ClassDiphenylmethanes
Direct ParentDiphenylmethanes
Alternative Parents
Substituents
  • Diphenylmethane
  • Phenylpropylamine
  • Phenol ester
  • Benzyl alcohol
  • Aralkylamine
  • Tertiary aliphatic amine
  • Tertiary amine
  • Carboxylic acid ester
  • Monocarboxylic acid or derivatives
  • Carboxylic acid derivative
  • Hydrocarbon derivative
  • Aromatic alcohol
  • Primary alcohol
  • Organooxygen compound
  • Organonitrogen compound
  • Carbonyl group
  • Amine
  • Alcohol
  • Aromatic homomonocyclic compound
Molecular FrameworkAromatic homomonocyclic compounds
External DescriptorsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Receptor activity
Specific Function:
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is Pi turnover.
Gene Name:
CHRM3
Uniprot ID:
P20309
Molecular Weight:
66127.445 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
  2. Nilvebrant L: Tolterodine and its active 5-hydroxymethyl metabolite: pure muscarinic receptor antagonists. Pharmacol Toxicol. 2002 May;90(5):260-7. [PubMed:12076307 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Guanyl-nucleotide exchange factor activity
Specific Function:
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is inhibition of adenylate cyclase.
Gene Name:
CHRM4
Uniprot ID:
P08173
Molecular Weight:
53048.65 Da
References
  1. Mansfield KJ, Chandran JJ, Vaux KJ, Millard RJ, Christopoulos A, Mitchelson FJ, Burcher E: Comparison of receptor binding characteristics of commonly used muscarinic antagonists in human bladder detrusor and mucosa. J Pharmacol Exp Ther. 2009 Mar;328(3):893-9. doi: 10.1124/jpet.108.145508. Epub 2008 Nov 24. [PubMed:19029429 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Phosphatidylinositol phospholipase c activity
Specific Function:
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is Pi turnover.
Gene Name:
CHRM1
Uniprot ID:
P11229
Molecular Weight:
51420.375 Da
References
  1. Nilvebrant L: Tolterodine and its active 5-hydroxymethyl metabolite: pure muscarinic receptor antagonists. Pharmacol Toxicol. 2002 May;90(5):260-7. [PubMed:12076307 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
G-protein coupled acetylcholine receptor activity
Specific Function:
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is adenylate cyclase inhibition. Signaling promotes phospholipase C activity, leading to the release of inositol trisphosphate (IP3); this then trigge...
Gene Name:
CHRM2
Uniprot ID:
P08172
Molecular Weight:
51714.605 Da
References
  1. Mansfield KJ, Chandran JJ, Vaux KJ, Millard RJ, Christopoulos A, Mitchelson FJ, Burcher E: Comparison of receptor binding characteristics of commonly used muscarinic antagonists in human bladder detrusor and mucosa. J Pharmacol Exp Ther. 2009 Mar;328(3):893-9. doi: 10.1124/jpet.108.145508. Epub 2008 Nov 24. [PubMed:19029429 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Phosphatidylinositol phospholipase c activity
Specific Function:
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is Pi turnover.
Gene Name:
CHRM5
Uniprot ID:
P08912
Molecular Weight:
60073.205 Da
References
  1. Mansfield KJ, Chandran JJ, Vaux KJ, Millard RJ, Christopoulos A, Mitchelson FJ, Burcher E: Comparison of receptor binding characteristics of commonly used muscarinic antagonists in human bladder detrusor and mucosa. J Pharmacol Exp Ther. 2009 Mar;328(3):893-9. doi: 10.1124/jpet.108.145508. Epub 2008 Nov 24. [PubMed:19029429 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Malhotra B, Guan Z, Wood N, Gandelman K: Pharmacokinetic profile of fesoterodine. Int J Clin Pharmacol Ther. 2008 Nov;46(11):556-63. [PubMed:19000553 ]
  2. Malhotra B, Dickins M, Alvey C, Jumadilova Z, Li X, Duczynski G, Gandelman K: Effects of the moderate CYP3A4 inhibitor, fluconazole, on the pharmacokinetics of fesoterodine in healthy subjects. Br J Clin Pharmacol. 2011 Aug;72(2):263-9. doi: 10.1111/j.1365-2125.2011.04007.x. [PubMed:21545485 ]
  3. Malhotra B, Sachse R, Wood N: Evaluation of drug-drug interactions with fesoterodine. Eur J Clin Pharmacol. 2009 Jun;65(6):551-60. doi: 10.1007/s00228-009-0648-1. Epub 2009 Apr 4. [PubMed:19347334 ]
  4. Malhotra BK, Wood N, Sachse R: Influence of age, gender, and race on pharmacokinetics, pharmacodynamics, and safety of fesoterodine. Int J Clin Pharmacol Ther. 2009 Sep;47(9):570-8. [PubMed:19761716 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic antidepressants.
Gene Name:
CYP2D6
Uniprot ID:
P10635
Molecular Weight:
55768.94 Da
References
  1. Malhotra B, Guan Z, Wood N, Gandelman K: Pharmacokinetic profile of fesoterodine. Int J Clin Pharmacol Ther. 2008 Nov;46(11):556-63. [PubMed:19000553 ]
  2. Malhotra B, Dickins M, Alvey C, Jumadilova Z, Li X, Duczynski G, Gandelman K: Effects of the moderate CYP3A4 inhibitor, fluconazole, on the pharmacokinetics of fesoterodine in healthy subjects. Br J Clin Pharmacol. 2011 Aug;72(2):263-9. doi: 10.1111/j.1365-2125.2011.04007.x. [PubMed:21545485 ]
  3. Malhotra B, Sachse R, Wood N: Evaluation of drug-drug interactions with fesoterodine. Eur J Clin Pharmacol. 2009 Jun;65(6):551-60. doi: 10.1007/s00228-009-0648-1. Epub 2009 Apr 4. [PubMed:19347334 ]
  4. Malhotra BK, Wood N, Sachse R: Influence of age, gender, and race on pharmacokinetics, pharmacodynamics, and safety of fesoterodine. Int J Clin Pharmacol Ther. 2009 Sep;47(9):570-8. [PubMed:19761716 ]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name:
ABCB1
Uniprot ID:
P08183
Molecular Weight:
141477.255 Da
References
  1. Chancellor MB, Staskin DR, Kay GG, Sandage BW, Oefelein MG, Tsao JW: Blood-brain barrier permeation and efflux exclusion of anticholinergics used in the treatment of overactive bladder. Drugs Aging. 2012 Apr 1;29(4):259-73. doi: 10.2165/11597530-000000000-00000. [PubMed:22390261 ]
Comments
comments powered by Disqus
Drug created on May 06, 2010 10:47 / Updated on December 05, 2016 02:42